The have put a ceiling on the stock....how stupid is this..they should think about selling stock after they open another 100 stores and make them profitable
8:02 am Habit Restaurants postpones proposed follow-on offering of common stock by certain stockholders in light of current capital market conditions (HABT) : The registration statement on Form S-1 has not been withdrawn and the Company and certain of the stockholders expect to continue to evaluate the potential for and timing of such secondary offering by certain of the Company's stockholders.
the headline says they expect to continue to evaluate the time for a sale of stock
What is the logic that this is just getting the weak hands out of the stock....They could open a lot of store have good earning but this kind of insider selling that was rejected but the street is not good... I got burned very badly with feye and this use the company as a piggy bank...we know another secondary is coming so why buy the stock until that is out of the way????
These analyst are a joke...in one day the target went from 123 to 23...its a complete joke
who's know yet but they bigger picture here is MORE REGULATION
they tried to sell themselves in the past and nobody wanted them ....now we know why...they analyst don't do anything but listen to the companies retoric...
its a disaster....the data is the data...i bought into this hype at 78 ...1). they had a great lung cancer breakthrough drug..this is not true 2). sales staff is hired this is true...drug is not going to be approved for a while if a all. The Analysts should all be fired
The situation just plain sucks ...down 70 percent with zero warning...A 15 mins call with half the analyst saying i missed the first part of the call...#$%$...
Clovis now says the confirmed response rates to the 500 mg and 625 mg doses of rociletinib are 28% and 34%, respectively. Those are lower than the response rates previously disclosed by Clovis.
The FDA has asked for additional efficacy data pertaining to these rociletinib doses. Clovis said the new information will be provided to FDA by the end of Monday but that the resubmission might delay the agency's approval timeline. Clovis was hoping to secure rociletinib's approval by March 30, 2016.
Any Details on what this new data is???